JRCT ID: jRCTs051210119
Registered date:09/11/2021
verification of ketogenic diet for lung cancer
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Lung Cancer |
Date of first enrollment | 12/01/2022 |
Target sample size | 40 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | ketogenic diet regimen using MCT combination beverage and MCT oil |
Outcome(s)
Primary Outcome | 1)Number and rate of adverse events of Grade 3 or higher up to 16 weeks 2)Continuation rate of ketognic diet at 16 weeks |
---|---|
Secondary Outcome | 1)Overall Survival 2)Progression-Free Survival 3)Duration of treatment at the time of participation in the study 4)Changes in scores of JFS and of Barthel Index 5)Changes in scores of EQ-5D and of FACT-L 6)Changes in scores of resilience scale 7)Body composition index (muscle mass, skeletal muscle index / SMI, body weight, fat mass (body fat mass / body fat percentage), extracellular water ratio, extracellular water content, phase angle, BMI) 8)Changes in Blood glucose monitoring 9)Changes in ABC score 10)Changes in Gut microbiota 11)Changes in Blood tumor marker |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | < 80age old |
Gender | Both |
Include criteria | 1)Patients who obtained written consent for this study 2)Patients who are 18 years old or older and under 80 years old at the time of informed consent 3)Patients who diagnosed with non-small cell lung cancer (NSCLC) 4)Patients whose clinical stage is stage IIIb or stage IV 5)Patients who undergoing standard lung cancer treatment 6)Patients whose PS (Performance Status) is 0-2 |
Exclude criteria | 1)Patients with diabetes who require treatment 2)Patients who have allergic episode with milk components 3)Patients who have difficulty ingesting orally 4)Patients who have difficulty in outpatient visits 5)Patients who are participating in or are planning to participate in clinical trials or other clinical studies 6)Patients who are considered ineligible to participate by principal investigator or sub-investigator |
Related Information
Primary Sponsor | Hagihara Keisuke |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | Meiji Holdings Co.,The Nisshin OilliO Group, Ltd.,Co-creation Bureau, Osaka University |
Secondary ID(s) |
Contact
Public contact | |
Name | Keisuke Hagihara |
Address | 2-2 Yamadaoka, Suita, Osaka, Japan Osaka Japan 565-0871 |
Telephone | +81-6-6210-8347 |
k.hagihara@kanpou.med.osaka-u.ac.jp | |
Affiliation | Osaka University Graduate School of Medicine |
Scientific contact | |
Name | Keisuke Hagihara |
Address | 2-15 Yamadaoka, Suita, Osaka, Japan Osaka Japan 565-0871 |
Telephone | +81-6-6210-8347 |
k.hagihara@kanpou.med.osaka-u.ac.jp | |
Affiliation | Osaka University Hospital |